To future. Paraguay is on the verge of a new dengue epidemic, which would peak during the holidays. Meanwhile, studies on vaccines and others that have already been approved are advancing.
The last one approved by the WHO for use was TAK-003. This biological prevents severe forms of dengue and can be applied to the population between 6 and 16 years old.
Dr. Águeda Cabello commented that the recommendation with this vaccine is that it be applied one to two years before the epidemic period.
So far, the product has been registered for commercial use in four Latin American countries. These are Brazil, Argentina, Mexico and Colombia. “In our country, registration of the vaccine in Dinavisa was not requested. But its use in the regular vaccination schedule is not yet indicated,” he noted.
He added that the PAHO report on its use is being awaited. From there, it will be seen if Takeda is included in the revolving vaccine fund.
It will also be clarified that its application will not be effective in the epidemic that will occur. “We also do not have to analyze applying the vaccine in this period that would be of greater hospitalization,” he stressed.
The approach to have the biological will be made for the period that will come later.
The person responsible for Health Surveillance pointed out that with the age group that can be immunized, not all citizens are being covered either.
A vaccine against chikungunya was recently approved in the United States. Regarding this biological, Dr. Cabello mentioned that there is still not much information.
“We don’t know if it will be marketed. We only know that it was approved in the United States,” he noted.
In the last three weeks there were 135 hospitalizations due to suspected arboviruses and deaths reached 18.
2023-11-16 07:00:00
#Dengue #epidemic #coming #vaccine
